Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has granted priority review to sonesitatug vedotin (Sone-Ve), an antibody-drug conjugate targeting CLDN18.2, for second-line or later treatment of advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma. Backed by phase 3 CLARITY-Gastric01 trial data, Sone-Ve doubled median overall survival in heavily pretreated patients compared to standard care. A decision is expected in Q2 2027.
The FDA has granted priority review to sonesitatug vedotin (Sone-Ve), a CLDN18.2-targeting antibody-drug conjugate (ADC) developed by AstraZeneca, for patients with previously treated locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma expressing CLDN18.2 in at least 25% of tumor cells. The target action date under PDUFA is Q2 2027.
The application is supported by the phase 3 CLARITY-Gastric01 trial, which enrolled 594 patients in the second-line or later setting. Sone-Ve met one of its dual primary endpoints — overall survival (OS) in the third-line or later population — and demonstrated a meaningful OS benefit across the broader intention-to-treat population. The PFS primary endpoint narrowly missed statistical significance. A second CLDN18.2-directed ADC, arcotatug tavatecan, also showed significant PFS and OS improvements in the phase 3 G-HOPE-001 trial, signaling a broader shift in this treatment landscape.
By the Numbers:
Why it matters: Patients with CLDN18.2-positive advanced gastroesophageal cancer have had no approved targeted options after first-line therapy. Sone-Ve is the first CLDN18.2-directed ADC to demonstrate an OS benefit in this setting, and its priority review status could accelerate access to a much-needed new treatment option for thousands of U.S. patients.